Bacterial Meningitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Bacterial meningitis or meningococcal meningitis is a type of meningitis caused by the bacteria Neisseria meningitidis. Meningitis is an inflammation of the membranes (meninges) surrounding the brain or spinal cord. This inflammation can start suddenly (acute) or gradually (progressive) (subacute). Symptoms may include fever, headache, stiff neck, and aching muscles. Nausea, vomiting, and other symptoms are possible. Rashes on the skin occur in roughly half of all meningococcal meningitis patients. The incubation period, which is the period of communicability, lasts an average of 3-4 days (range 1-10 days). It spreads faster than any other type of acute bacterial meningitis. Meningococcal meningitis involves the central nervous system. It is often preceded by respiratory illness or a sore throat in adults and children. Meningococcemia is distinguished by severe, widespread vascular injury, evidence of circulatory collapse, and diffuse intravascular coagulation (DIC). The disorder is characterized by fever, headache, stiff neck, nausea, vomiting, and altered mental states such as confusion or coma in its acute form. Adults can become seriously ill in a matter of hours. The duration of the infection may be even shorter in children. Rashes on the skin occur in roughly half of all meningococcal meningitis patients.
·
In the United States, the incidence of
Meningococcal meningitis ranges from 1 to 1.45 cases per 100,000 people. Males
are slightly more affected than females, accounting for 55% of all cases.
Infants, children, and young adults are the most vulnerable to meningococcal
meningitis.
Thelansis’s “Bacterial Meningitis
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2022 To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Bacterial Meningitis treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Bacterial Meningitis across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Bacterial Meningitis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment